January 2nd 2025
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
Watch the series now!
Family Caregivers of Cancer Patients Vulnerable to Depression, Anxiety
Most US Adults Favor Prohibiting Tobacco Sales in Retail Pharmacies
Atezolizumab's Success in NSCLC Spells Further Trouble for Nivolumab